Meeting
2013 ASCO Annual Meeting
Open-label, multicenter safety study of vemurafenib in patients with BRAFV600 mutation–positive metastatic melanoma.
Authors
James M. G. Larkin
The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom
James M. G. Larkin , Michele Del Vecchio , Paolo Antonio Ascierto , Jacob Schachter , Claus Garbe , Bart Neyns , Mario Mandala , Paul Lorigan , Wilson H Miller , Alexander David Guminski , Carola Berking , Piotr Rutkowski , Paola Queirolo , Axel Hauschild , Ana Maria Arance , Michael Paul Brown , Lada Mitchell , Maria Luisa Veronese , Christian U. Blank
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT01307397
Citation
J Clin Oncol 31, 2013 (suppl; abstr 9046)
DOI
10.1200/jco.2013.31.15_suppl.9046
Abstract #
9046
Poster Bd #
45A
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity.
First Author: Ryan J. Sullivan
Poster
2012 ASCO Annual Meeting
An open-label, multicenter safety study of vemurafenib (PLX4032, RO5185426) in patients with metastatic melanoma.
First Author: James M. G. Larkin
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I.
First Author: Georgina V. Long
Poster
2019 ASCO Annual Meeting
The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i.
First Author: Georgina V. Long